US VAC permissions granted for Episurf Medical
Episurf Medical (Nasdaq: EPIS B) today announces several recent permissions granted from health systems’ Value Analysis Committees (VACs) within the United States. While typical sales cycles begin with interest from an orthopaedic surgeon, review and access to begin doing surgeries must almost always first be granted by individual VACs. Recently, among others, the company has received approval to initiate surgeries within facilities at:
- Vail Health System (affiliated with the Steadman Clinic) – Vail, Colorado
- The Hospital for Special Surgery – New York, New York
- Dartmouth Health System – Lebanon, New Hampshire
“VAC approvals are a pivotal step in our sales cycles. While we often think of our customers as orthopaedic surgeons and while this is true to some degree, in reality hospitals, surgery centers, and healthcare systems are the entities actually purchasing our products. We’re grateful some of the country’s leading and most prestigious health systems have recently granted us access, and we are looking forward to beginning productive commercial relationships with each of them,” said Patrick Jamnik, President of Episurf Medical, Inc.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 27 December 2024.
Tags: